Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a commercial-stage biopharmaceutical company with a promising drug candidate VTAMA and several other drugs in different stages of development. The positive Phase 2 data for brepocitinib in multiple indications, strong hemodynamic profile for mosliciguat, and the validation of the anti-FcRn mechanism by multiple developers make Roivant Sciences a promising investment opportunity. However, there are risks to consider, such as regulatory and clinical uncertainties, competition in the market, and potential technical hurdles.

Bears say

Roivant Sciences is in its commercial stage, but its management has set expectations for a measured initial ramp for its plaque psoriasis treatment, VTAMA. Additionally, success in this indication has been the primary driver of the company's performance but upcoming data readouts and the potential expansion into other indications could also contribute to its success. However, investors should expect a slow and steady launch for VTAMA, and the company's other drug candidates in development may face challenges in uptake due to barriers like safety concerns and lack of physician familiarity.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.